Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Melanoma, Cutaneous Malignant × Ipilimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 18 Carcinoma, Non-Small-Cell Lung 10 Carcinoma, Renal Cell 9 Kidney Neoplasms 4 Stomach Neoplasms 3 Mesothelioma 3 Lung Neoplasms 3 Diabetes Mellitus, Insulin-Dependent, 12 3 Carcinoma, Hepatocellular 3 Skin Neoplasms 2 Prostatic Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Neoplasm Metastasis 2 Mesothelioma, Malignant 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Various Advanced Cancer 1 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Recurrent Squamous Cell Lung Carcinoma 1 Recurrence 1 Non-Small Cell Lung Cancer Metastatic 1 Neoplasms 1 Melanoma, Cutaneous Malignant 1 Lymphatic Metastasis 1

Interventions

relatlimab 1 pembrolizumab 1 lifileucel 1 Vitamin D 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Dacarbazine 1 Cholecalciferol 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06743126 2026-04-13

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡